In terms of clinical application, the GPX4 agonist selenomethionine (Se-Met) upregulates GPX4 expression in a liver cancer model, and in combination with a PD-1 antibody, it significantly improves the complete response rate (CR) (183). Here, GPX4 is linked to liver cancer.